<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04586478</url>
  </required_header>
  <id_info>
    <org_study_id>HY001205</org_study_id>
    <nct_id>NCT04586478</nct_id>
  </id_info>
  <brief_title>Phase II Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma</brief_title>
  <official_title>Phase II Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Juventas Cell Therapy Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Juventas Cell Therapy Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is a Phase II, single-arm, open-label, single-dose clinical trial, and its primary&#xD;
      objective is to evaluate the efficacy and safety of CNCT19 Cell Injection in the treatment of&#xD;
      relapsed or refractory NHL.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is a Phase II, single-arm, open-label, single-dose clinical trial, and its primary&#xD;
      objective is to evaluate the efficacy and safety of CNCT19 Cell Injection in the treatment of&#xD;
      relapsed or refractory NHL. The study consists of screening period (8 weeks), treatment&#xD;
      period (4 weeks), and follow-up period (2 years at most).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 26, 2020</start_date>
  <completion_date type="Anticipated">March 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Remission Rate (ORR), which includes Complete Remission (CR) and Partial Remission (PR)</measure>
    <time_frame>3 months</time_frame>
    <description>Efficacy of CNCT19 as measured by ORR during the 3 months after CNCT19 Cell Injection infusion, which includes CR and PR.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complete Remission (CR)</measure>
    <time_frame>3 months</time_frame>
    <description>Efficacy of CNCT19 as measured by CR during the 3 months after CNCT19 Cell Injection infusion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ORR（CR+PR）/CR</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ORR（CR+PR）/CR</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>24 months</time_frame>
    <description>PFS means duration from the CNCT19 Cell Injection infusion to progression of lymphoma, or death for any reason.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-free survival (DFS)</measure>
    <time_frame>24 months</time_frame>
    <description>DFS means duration from the beginning of complete remission to relapse of disease, or death (for any reason).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Remission (DOR)</measure>
    <time_frame>24 months</time_frame>
    <description>DOR means the duration from reaching the response (e.g., CR or PR) criteria of the therapy to the first, clearly defined progressive disease, or death for disease under investigation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best Overall Response (BOR)</measure>
    <time_frame>24 months</time_frame>
    <description>The best overall response after CNCT19 infusion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>24months</time_frame>
    <description>OS means duration from the CNCT19 Cell Injection infusion to death for any reason, or the last follow-up for survival.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to remission (TTR)</measure>
    <time_frame>24 months</time_frame>
    <description>TTR means duration from the CNCT19 Cell Injection infusion to the first response (irrespective of PR or CR, which comes first).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Non-Hodgkin's Lymphoma</condition>
  <arm_group>
    <arm_group_label>Single dose of CNCT19</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A conditioning chemotherapy regimen of fludarabine and cyclophosphamide will be administered followed by investigational treatment, CNCT19.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>single dose of CNCT19</intervention_name>
    <description>Dose: 2.00 x 10^8 CNCT19 Cell Injection via intravenous infusion. Drug: Fludarabine Drug: Cyclophosphamide</description>
    <arm_group_label>Single dose of CNCT19</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients who are willing to sign the informed consent form;&#xD;
&#xD;
          2. Aged 18-75 years, male or female;&#xD;
&#xD;
          3. At screening, subjects complying with the following diagnostic and treatment&#xD;
             requirements:&#xD;
&#xD;
               1. Complying with CD19-positive NHL according to the WHO classification 2017, which&#xD;
                  are provided specifically as follows:&#xD;
&#xD;
                    -  Diffuse large B cell lymphoma (DLBCL), not otherwise specified (NOS);&#xD;
&#xD;
                    -  Primary mediastinal large B cell lymphoma (PMBCL);&#xD;
&#xD;
                    -  Transformed follicular lymphoma&#xD;
&#xD;
                    -  High grade B cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements, and&#xD;
                       high grade B cell lymphoma - not otherwise specified.&#xD;
&#xD;
               2. Previously received≥2nd-line adequate therapy or autologous hematopoietic stem&#xD;
                  cell transplantation (ASCT), including:&#xD;
&#xD;
                    -  Received at least Rituximab or other CD20 targeted drugs containing (except&#xD;
                       CD20 negative tumors) chemotherapy and&#xD;
&#xD;
                    -  Received at least one chemotherapy regimen containing anthracycline;&#xD;
&#xD;
                    -  Definition of line: Stable disease (SD) after receiving a first-line therapy&#xD;
                       for at least 4 cycles or progressive disease (PD), and SD after a&#xD;
                       second-line therapy for at least 2 cycles or PD .&#xD;
&#xD;
             a.c. In relapsed or refractory status at screening:&#xD;
&#xD;
               -  Definition of relapse: Remission (including partial remission (PR) or complete&#xD;
                  remission (CR)) after treatment with at least the standard therapy regimen (it&#xD;
                  must contain Ribuximab), and then PD;&#xD;
&#xD;
               -  Definition of refractoriness:&#xD;
&#xD;
             Non-responsiveness to the last therapy: The best response by the last therapy is SD or&#xD;
             PD; Relapse or progression after ASCT, including: Relapse (it must be proved by&#xD;
             biopsy) or PD within 12 months after ASCT; if a rescue therapy is received, the&#xD;
             patient is non-responsive (SD or PD) to the last therapy;&#xD;
&#xD;
             • For transformed follicular lymphoma (TFL), patients must be treated adequately&#xD;
             against FL, and after transformation, must have received at least once the therapy&#xD;
             against TFL, and become relapsed or refractory after the last therapy.&#xD;
&#xD;
          4. Measurable imaging lesion at screening: Intranodal lesion must have a long diameter of&#xD;
             more than 1.5 cm, and extranodal lesion must have a long diameter of more than 1.0 cm&#xD;
             (per revised IWG Response Criteria 2014 in Lymphomas);&#xD;
&#xD;
          5. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1;&#xD;
&#xD;
          6. Adequate bone marrow reserve, defined as:&#xD;
&#xD;
               -  Absolute neutrophil count (ANC) &gt; 1.0×109/L;&#xD;
&#xD;
               -  Absolute lymphocyte count (ALC) ≥ 0.3×109/L;&#xD;
&#xD;
               -  Platelet (PLT) ≥50×109/L;&#xD;
&#xD;
          7. Proper organ function, complying with the following criteria (except hepatic&#xD;
             dysfunction due to tumor cell infiltration): Aspartate aminotransferase (AST) ≤ 3&#xD;
             Upper Limit of Normal (ULN); Alanine aminotransferase (ALT) ≤ 3 ULN; Total serum&#xD;
             bilirubin ≤ 2 ULN, unless there exists concurrent Gilbert syndrome; patients with&#xD;
             Gilbert syndrome, with total serum bilirubin ≤ 3 ULN and direct bilirubin ≤ 1.5 ULN,&#xD;
             may be included; Renal function: serum creatinine ≤ 1.5 ULN or creatinine clearance ≥&#xD;
             60 mL/min (Cockcroft-Gault formula); Minimum pulmonary reserve, defined as Grade ≤ 1&#xD;
             dyspnea, and blood oxygen saturation &gt; 91% at non-oxygen inhalation status;&#xD;
             International normalized ratio (INR) ≤ 1.5 ULN and activated partial thromboplastin&#xD;
             time (aPTT) ≤ 1.5 ULN.&#xD;
&#xD;
          8. Vascular conditions for apheresis;&#xD;
&#xD;
          9. Women with child-bearing potential are negative in blood/urine pregnancy tests within&#xD;
             3 d prior to apheresis, and prior to infusion of CNCT19 cell injection infusion; any&#xD;
             male or female patient with child-bearing potential must agree to adopt effective&#xD;
             contraceptive measures throughout the study, and at least half a year after&#xD;
             administration of the investigational therapy. As judged by the investigator, a&#xD;
             patient with child-bearing potential means that: He/she has normal sexual life and is&#xD;
             biologically fertile to have children. Non-fertile female patients (i.e., complying&#xD;
             one of the following criteria):Previously received hysterectomy, bilateral&#xD;
             ovariectomy, or bilateral tubal ligation, or Medically confirmed ovarian failure, or&#xD;
             Medically confirmed postmenopause (amenorrhea of at least 12 consecutive months).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with active central nervous system (CNS) lymphoma (a patient with CNS disease&#xD;
             symptoms must receive lumbar puncture and MRI/CT to exclude CNS lymphoma).&#xD;
&#xD;
          2. Patients with existing central nervous system disease or with a history of central&#xD;
             nervous system disease, e.g., epileptic seizure, cerebral ischemia/hemorrhage,&#xD;
             paralysis, aphasia, stroke, severe brain injury, dementia, Parkinson's disease,&#xD;
             cerebellum disease, organic brain syndrome, mental disease, or any autoimmune disease&#xD;
             involved with central nervous system.&#xD;
&#xD;
          3. Patients receiving any of the following drugs or therapies within the specified period&#xD;
             prior to apheresis:&#xD;
&#xD;
               -  Alemtuzumab within 6 months prior to apheresis;&#xD;
&#xD;
               -  Cladribine within 3 months prior to apheresis;&#xD;
&#xD;
               -  Anti-CD20 monoclonal antibody within 7 d prior to apheresis;&#xD;
&#xD;
               -  Venetoclax (BCL-2 inhibitor) within 4 d prior to apheresis;&#xD;
&#xD;
               -  Idelalisib (PI3Kδ kinase inhibitor) within 2 d prior to apheresis;&#xD;
&#xD;
               -  Lenalidomide within 1 d prior to apheresis;&#xD;
&#xD;
               -  Lymphocytotoxic chemotherapy within 2 weeks prior to apheresis - use in more than&#xD;
                  3 half-lives prior to apheresis is eligible;&#xD;
&#xD;
               -  Non-lymphocytotoxic chemotherapy within 7 d prior to apheresis - use in more than&#xD;
                  3 half-lives prior to apheresis is eligible;&#xD;
&#xD;
               -  Radiotherapy within 6 weeks prior to apheresis, including big bone marrow area&#xD;
                  (e.g., sternum or pelvis) - progressive disease at radiotherapy site, or PET&#xD;
                  positive lesion at other non-radiotherapy site is eligible; if there is existing&#xD;
                  PET positive lesion in other non-radiotherapy sites, then it is allowable to&#xD;
                  conduct radiotherapy at a single lesion within 2 weeks prior to apheresis.&#xD;
&#xD;
          4. Patients receiving chemotherapy within 2 weeks prior to CNCT19 Cell injection&#xD;
             infusion, excluding the following conditions:&#xD;
&#xD;
               -  Pretreatment chemotherapy as specified by the protocol;&#xD;
&#xD;
               -  CNS lymphoma prophylaxis by intrathecal injection (it must be stopped within 1&#xD;
                  week prior to infusion of CNCT19 Cell Injection).&#xD;
&#xD;
          5. Discontinuation of a systematic therapeutic hormone within 72 h prior to infusion of&#xD;
             CNCT19 Cell Injection; however, use of the hormone in the physiological surrogate&#xD;
             amount is eligible (e.g., Prednisone in a dose of &lt;10 mg/d or equivalent).&#xD;
&#xD;
          6. Patients previously received CAR-T cell therapy.&#xD;
&#xD;
          7. Patients who have previously received allogeneic hematopoietic stem cell&#xD;
             transplantation (allo-HSCT).&#xD;
&#xD;
          8. Patients with known systemic vasculitis (e.g., Wegener granuloma and polyarteritis),&#xD;
             systemic lupus erythematosus, concurrent active or uncontrolled autoimmune disease&#xD;
             (e.g., Crohns disease, rheumatoid arthritis, or autoimmune hemolytic anemia), primary&#xD;
             or secondary immunodeficiency (e.g., HIV infection or severe infectious disease).&#xD;
&#xD;
          9. Patients complying with any of hepatitis B surface antigen (HBsAg) and/or hepatitis B&#xD;
             e antigen (HBeAg) positive, hepatitis B e antibody (HBe-Ab) and/or hepatitis B core&#xD;
             antibody (HBc-Ab) positive and HBV-DNA copies being more than the lower limit of&#xD;
             detection, hepatitis C antibody (HCV-Ab) positive, anti-treponemia pallidum antibody&#xD;
             (TP-Ab) positive, EBV-DNA, and CMV-DNA copies being more than the lower limit of&#xD;
             detection.&#xD;
&#xD;
         10. Patients who received a major surgery within 4 weeks prior to screening, and are not&#xD;
             eligible for enrollment as judged by the investigator.&#xD;
&#xD;
         11. Patients with concurrent active malignancy; those with a history of malignancy, cured&#xD;
             for≥2 years, are eligible.&#xD;
&#xD;
         12. Patients complying any of the following conditions: Left ventricular ejection fraction&#xD;
             (LVEF) ≤45% (ECHO); New York Heart Association (NYHA) Grade III or IV congestive heart&#xD;
             failure; Severe arrhythmia requiring treatment, including QTc interval≥450 ms in&#xD;
             males, or ≥470 ms in females (QTcB = QT/RR1/2); Uncontrolled hypertension (systolic&#xD;
             blood pressures≥140mmHg and/or diastolic blood pressures ≥90 mmHg), pulmonary&#xD;
             hypertension, or unstable angina pectoris; Myocardial infarction or bridging or stent&#xD;
             procedure within 12 months prior to administration of the drug; Clinically significant&#xD;
             valvular heart disease; Other heart diseases unsuitable for enrollment, as judged by&#xD;
             the investigator.&#xD;
&#xD;
         13. Patients with lymphoma involved with atrium or ventricle.&#xD;
&#xD;
         14. Patients with clinical emergency (e.g., intestinal infarction or vascular compression)&#xD;
             requiring treatment, due to existing lymphoma body obstruction or compression at&#xD;
             screening.&#xD;
&#xD;
         15. Patients with active hemorrhage at screening.&#xD;
&#xD;
         16. Patients with deep vein thrombosis within 6 months prior to screening, or a history of&#xD;
             pulmonary embolism.&#xD;
&#xD;
         17. Patients who are known with a history of hypersensitivity reaction to any ingredient&#xD;
             used for the drug product in the trial.&#xD;
&#xD;
         18. Patients vaccinated with a live vaccine within 6 weeks prior to screening.&#xD;
&#xD;
         19. Patients with active infection at screening.&#xD;
&#xD;
         20. Patients with a life expectancy of less than 3 months.&#xD;
&#xD;
         21. Patients participating in any other interventional clinical study or receiving&#xD;
             treatment of an active investigational drug within 3 months prior to CNCT19 Cell&#xD;
             Injection infusion, or who are planned to participate in another clinical study or to&#xD;
             receive an antitumor therapy not specified in the protocol.&#xD;
&#xD;
         22. Patients with other conditions that are not suitable to participate in the clinical&#xD;
             trial, as considered by the investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dehui Zou, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute of Hematology &amp; Blood Diseases Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Weili Zhao, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ruijin Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jianhui Sun</last_name>
    <phone>+8618910738020</phone>
    <email>sunjianhui@juventas.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Fujian Medical University Union Hospital</name>
      <address>
        <city>Fuzhou</city>
        <state>Fujian</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jianda Hu, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Guangdong Provincial Peoples' Hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wenyu Li, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Henan Cancer Hospital</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Keshu Zhou, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Zhengzhou University</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mingzhi Zhang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tongji Hospital, Tongji Medical College of HUST</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jianfeng Zhou, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jiangsu Province Hospital</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jianyong Li, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Qilu Hospital of Shandong University</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chuanli Zhao, Dr.</last_name>
      <phone>+86 185 6008 7009</phone>
      <email>chuanlizhao@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>West China Hospital，Sichuan University</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ting Niu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital, Zhejiang University school of Medicine</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jie Jin, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beijing Boren Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kai Hu, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beijing Cancer Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yuqin Song, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Peking University First Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hanyun Ren, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Peking University Third Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hongmei Jing, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Chongqing Medical University</name>
      <address>
        <city>Chongqing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lin Liu, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Xinqiao Hospital of TMMU</name>
      <address>
        <city>Chongqing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xi Zhang, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ruijin Hospital, Shanghai Jiaotong University School of Medicine</name>
      <address>
        <city>Shanghai</city>
        <zip>200025</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Weili Zhao, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tongji Hospital of Tongji University</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Aibin Liang, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institute of Hematology &amp; Blood Diseases Hospital</name>
      <address>
        <city>Tianjin</city>
        <zip>300020</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dehui Zou, Dr.</last_name>
      <phone>+86-13602100955</phone>
      <email>zoudehui@ihcams.ac.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>October 8, 2020</study_first_submitted>
  <study_first_submitted_qc>October 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 14, 2020</study_first_posted>
  <last_update_submitted>February 9, 2021</last_update_submitted>
  <last_update_submitted_qc>February 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

